TL;DR
Get travel and outdoor gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
In an interview published by The Quantum Insider on Oct. 3, Helmut Katzgraber, general partner at quantum-focused venture fund 55North, argued that near- to medium-term quantum applications are more promising in simulation for materials, chemicals and pharmaceuticals than in optimization. He said classical computing is likely to outperform quantum devices on optimization for the foreseeable future, while the timing and commercial value of quantum simulation remain unproven.
Helmut Katzgraber, general partner at quantum-focused venture fund 55North and a former quantum leader at AWS, says the strongest near- to medium-term case for quantum computing is simulating materials, chemicals and pharmaceuticals—not solving optimization problems. In an interview published by The Quantum Insider on Oct. 3, 2026, he said classical computing is likely to outperform quantum devices on optimization for the foreseeable future, while quantum simulation could eventually help with problems that are difficult for classical machines.
Katzgraber based his view on the fit between quantum hardware and the problems it is designed to represent. He pointed to quantum-mechanical simulations of materials and chemical systems as a potential source of early practical value. Examples he named included strongly correlated systems in battery materials, organic LEDs and some medicines containing metal-organic complexes, where he said classical computing struggles.
He did not say that quantum devices have already delivered a commercial advantage in these areas. Katzgraber described the prospective value as something quantum technologies may bring down the road. During the interview, he referred to a recent paper reporting a material simulated on a neutral-atom machine, but the source material does not identify the paper, its results or whether the demonstration outperformed a classical method.
On optimization, Katzgraber said he was “relatively bullish” that classical technologies will outperform quantum devices for the foreseeable future. He was more cautious about quantum machine learning, describing it as an immature area where more remains to be learned. The interview also covered venture investment, deployment models and the challenge of turning European research into commercial products, but it did not announce a new 55North investment or a specific company launch.
Where Quantum May Find Early Value
The distinction matters for researchers, companies and investors deciding which quantum use cases to pursue. If Katzgraber’s assessment proves right, near-term progress is more likely to come from workloads that directly model quantum systems than from broad promises to improve general optimization. That would shape choices about hardware development, software tools and research funding, as well as which commercial milestones investors track.
His comments also temper expectations about quantum computing as a general-purpose upgrade. A possible advantage in a narrow class of materials or chemical simulations would not mean quantum computers can broadly outperform classical machines. The practical test remains whether a device can solve a relevant problem at useful scale, with results that classical approaches cannot match at comparable cost and effort.
For venture investors, Katzgraber described a mix of time horizons. He said some enabling technologies—such as refrigeration and software for error-correction models—could serve multiple hardware approaches and may produce returns within a fund’s lifetime. That is an investment perspective, not evidence that those returns are guaranteed.
quantum materials simulation software
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From AWS Research to 55North
Katzgraber told interviewer Yuval Boger that he is now a general partner at 55North, a Denmark-based venture fund focused on quantum technologies. Before joining the fund, he led a team of quantum scientists at AWS; he also described experience at Microsoft and academic work at Texas A&M. He said that work gave him several years of exposure to questions about which problems quantum devices may—and may not—handle effectively.
The interview connects his technical view to a broader commercial challenge: moving research out of laboratories and into products. Asked whether Europe can compete with the United States and China in quantum computing, Katzgraber gave a qualified answer. He praised Europe’s talent and research ecosystem, but said the pipeline becomes less reliable when the task is turning laboratory ideas into products. The interview excerpt does not provide comparative investment figures, company counts or other data to measure that gap.
“Use quantum where quantum reigns supreme, you know, in the quantum world.”
— Helmut Katzgraber, general partner at 55North
chemical simulation tools for researchers
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Evidence and Commercial Timelines
The interview presents Katzgraber’s assessment, not proof that quantum simulation has achieved a practical advantage over classical computing. The referenced neutral-atom demonstration is not described in enough detail in the source material to assess its scale, accuracy, cost or comparison with classical methods. It is also unclear which specific materials or chemical problems could be commercially useful first, and when a quantum device might solve them better in practice.
His comments do not establish that every optimization task will remain better suited to classical computing, nor do they rule out future results that could change the comparison. No performance data, customer deployments, revenue milestones or new 55North investments were announced in the interview excerpt. The commercial timing for the applications Katzgraber discussed remains uncertain.
molecular modeling software for pharmaceuticals
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Tests That Could Validate the Case
The next meaningful evidence will come from detailed demonstrations showing whether quantum devices can simulate relevant materials or chemical systems with useful accuracy and scale, and how those results compare with the strongest classical methods. Reports will need to make clear what was simulated, what resources were used and whether the result advances a real research or industrial task rather than a limited benchmark.
For investors and companies, the questions raised in the interview also point to progress in enabling technologies, error-correction software and the movement of research into products. Katzgraber did not identify a specific upcoming announcement or deadline. Until such evidence or a company milestone is reported, his comments remain a view on where quantum computing may deliver value—not confirmation that it has done so.
quantum computing hardware for materials science
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What quantum application does Katzgraber see as most promising?
He favors quantum-mechanical simulation for materials, chemicals and pharmaceuticals, especially systems he says are difficult for classical computing to model.
Does the interview show that quantum computers have beaten classical computers at materials simulation?
No. Katzgraber referred to a recent neutral-atom simulation, but the interview excerpt does not provide results showing a practical advantage over classical methods.
What did Katzgraber say about quantum optimization?
He said classical technologies are likely to outperform quantum devices on optimization for the foreseeable future. This is his assessment, not a guarantee about every optimization problem or future hardware.
What did Katzgraber say about Europe’s quantum sector?
He praised Europe’s talent and research environment but said the path from laboratory research to commercial products is a weak point. The interview did not include data quantifying that gap.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
